Eli Lilly Partners with Superluminal for $1.3 Billion AI Drug Discovery Deal

Eli Lilly (LLY) has partnered with Superluminal for AI drug discovery, worth $1.3 billion, to develop small-molecule drugs for obesity and other cardiometabolic diseases using AI-driven platforms targeting G-protein-coupled receptors. The deal aims to solidify LLY's foothold in the obesity treatment market, projected to reach $150 billion by the next decade.